These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23313304)

  • 1. A comparison of the PANSS pentagonal and Van Der Gaag 5-factor models for assessing change over time.
    Jerrell JM; Hrisko S
    Psychiatry Res; 2013 May; 207(1-2):134-9. PubMed ID: 23313304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in cognitive function associated with syndrome changes on two five-factor models of the Positive and Negative Syndrome Scale.
    Jerrell JM; Hrisko S
    Hum Psychopharmacol; 2012 Nov; 27(6):566-76. PubMed ID: 23817989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
    Stefanovics EA; Krystal JH; Rosenheck RA
    Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
    Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS).
    Khan A; Yavorsky WC; Liechti S; DiClemente G; Rothman B; Opler M; DeFries A; Jovic S
    J Clin Psychopharmacol; 2013 Feb; 33(1):109-17. PubMed ID: 23277234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
    J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group.
    White L; Harvey PD; Opler L; Lindenmayer JP
    Psychopathology; 1997; 30(5):263-74. PubMed ID: 9353855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
    Levine SZ; Rabinowitz J
    J Clin Psychopharmacol; 2007 Oct; 27(5):431-6. PubMed ID: 17873671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.
    Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB
    Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia.
    Jerrell JM; Hrisko S
    Schizophr Res Treatment; 2013; 2013():705631. PubMed ID: 24381761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
    Casey DE; Daniel DG; Tamminga C; Kane JM; Tran-Johnson T; Wozniak P; Abi-Saab W; Baker J; Redden L; Greco N; Saltarelli M
    Neuropsychopharmacology; 2009 Apr; 34(5):1330-8. PubMed ID: 19052541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
    Citrome L; Meng X; Hochfeld M
    Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
    Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
    Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
    Liu-Seifert H; Osuntokun OO; Feldman PD
    Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.